Trump Decree Cuts Drug Prices by 30-80%

Trump Decree Cuts Drug Prices by 30-80%

Donald Trump announced a decree reducing prescription drug prices in the United States by between 30% and 80%. He made the announcement via a message promising to sign "one of the most important executive orders in our country's history" at the White House, citing figures that sound like campaign headlines: prices will drop "almost immediately," saving the country "trillions of dollars." The fine print—who pays the difference and what happens to the rest of the world—is where the problems begin.

The mechanism announced is a most-favored-nation policy: the US will pay for each drug the same price as the nation buying it cheapest. On paper, the idea is simple. In practice, it implies redistributing the differential currently borne by American patients. This is where consensus breaks down.

The €18 EpiPen vs. the $3,000 One

The example circulating is the auto-injectable adrenaline. In Spain, an EpiPen costs between €5 and €18. In the US, the same device has sold for figures multiplying that range to extremes hard to justify. It’s not a new drug or recent development: it’s a gadget with a fortified patent and no real competition.

That is the core of the problem. The company controlling the auto-injector patent has no rival, so without competition, it sets whatever price suits it. There are no generics to replace it, no parallel imports to pressure it. A captive market does the rest.

Why Are Drugs More Expensive in the US?

Short answer: because US legislation prevents internal competition and blocks imports from countries where the same drug costs a fraction. This creates a protected market where labs compete against no one. The long answer includes collusion between pharmaceutical companies and insurers to inflate prices, over-regulation, and entry barriers only large players can afford.

One case illustrates the chaos better than any graph. The insulin patent was sold for a symbolic price to make treatment affordable to anyone needing it. Decades later, the product that cost two dollars sells for two hundred, and the one that cost thirty has gone to two thousand. We aren’t talking about new molecules with research behind them: we’re talking about drugs older than cough itself.

Price Control: The Label No One Wants

Here things get interesting. The measure is, in practice, price control. That clashes with Trump’s narrative as a free-market champion. Liberal orthodoxy defenders argue intervening in a regulated sector’s price leads to shortages: if labs can’t earn expected profits, they stop manufacturing, and patients lose. The argument has centuries of history and isn’t always wrong.

Opposing this is pragmatic calculation: if insulin drops from €300/month to $10 or $15, as in Spain, ideological debate becomes secondary. Those framing it this way don’t defend the decree out of conviction, but results. That’s the point confusing allies and opponents alike.

Comparisons with Spain appear several times. Here, prices are negotiated with the ministry; labs can raise them if they want, but if excluded from public funding, no one pays full price except those using private care without checking bills. Competition among labs does the rest: you can set any price only if your drug is unique in its class.

Who Pays the Bill?

The overarching question is distribution. If pharma won’t give up margins, money currently paid by US patients must come from elsewhere. Most repeated hypothesis: it shifts to other countries, seeing prices rise to match the new floor. The announcement hints at this when stating prices "will increase worldwide to equalize."

This makes the measure a zero-sum game with a trap: the US pays less, others pay more. For Europe, and Spain specifically, the pharmaceutical bill could rise if labs compensate via markets where they still have margin. No one has yet explained how to avoid this effect.

The Precedent No One Cites

It’s not the first time a government intervenes in essential product pricing. Masks and ELbichito tests had regulated prices. Butane gas bottles have had capped prices for decades. In none of these cases did companies collapse or products disappear. Thus, the shortage argument has recent counterexamples.

What changes the calculation is scale. Regulating gas bottles is one thing. Interfering with the US pharmaceutical sector, with its lobbies, cross-patents, and GDP weight, is quite another. That’s where the decree might remain just an announcement if courts or Congress block it.

What Remains to Be Seen

The announcement promises signing at the White House and cuts "almost immediately." Reality has more steps: the order may end up in court, Congress may overturn it, and pharma has lawyers and time. Meanwhile, the gap between drug costs in Spain and the US persists, unexplained why the same product, made in the same plant, costs five or ten times more across the Atlantic.

What if the decree ultimately serves only to make the rest of the world pay the bill Americans currently bear?